Blog

Marco Donia: Pleased to be Co-chairing with Timothée Olivier in an educational session at ESMOImmuno24

Marco Donia and Timothée Olivier

Nov 14, 2024, 17:48

Marco Donia: Pleased to be Co-chairing with Timothée Olivier in an educational session at ESMOImmuno24

Marco Donia, Senior Consultant, Clinician-Scientist and Junior Research Group Leader (TIL group) at University of Copenhagen Herlev Hospital, shared a post by ESMO – European Society for Medical Oncology on LinkedIn:

“Very pleased to be co-chairing with Timothée Olivier and speaking in an educational session: “Real-World Benefits of Immunotherapy.”

Click here to watch the program.

ESMOImmuno24 in Geneva (CH), 11-13 Dec 2024.
Deadline for reduced registration rate is TODAY.”

Quoting ESMO – European Society for Medical Oncology‘s post:

“ESMOImmuno24:

Last Chance to Save on Registration.

Exciting times ahead! Late-breaking abstract authors-titles are now online!
Head to the programme to see the science you can look forward to and register today.

Why Attend?

Cutting-edge research & breakthroughs in cancer treatment
Leading experts & clinical insights
Networking with global oncology professionals

Our international speakers and experts have designed a comprehensive programme, offering a great opportunity for you to be at the forefront of this rapidly evolving field.
Meet us in Geneva, Switzerland or online and access recent scientific developments in this promising field.

Click here to register now.

To watch full video, Click here.”

Marco Donia is a Senior Consultant, Clinician-Scientist and Junior Research Group Leader (TIL group) at the Department of Oncology and Center for Cancer Immune Therapy, University of Copenhagen Herlev Hospital, Denmark. He serves as an Associate Professor in Clinical Oncology at the University of Copenhagen. Donia is also a clinical oncologist treating patients with cancer immunotherapy. His research group is currently investigating new immune-regulatory circuits in PD-1/PD-L1 resistant tumors.